Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$160.86
+1.0%
$157.07
$111.09
$183.00
$9.81B0.41486,491 shs55,508 shs
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$13.59
+2.7%
$14.12
$11.51
$21.50
$2.37B0.55100,245 shs10,797 shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.82
+2.9%
$26.70
$23.15
$158.82
$10.36B1.998.03 million shs4.02 million shs
Qiagen stock logo
QGEN
Qiagen
$44.89
+1.1%
$41.49
$37.63
$49.30
$9.98B0.671.32 million shs320,938 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.25%+0.72%-3.42%+3.98%+25.06%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
-1.34%+0.08%-12.27%-20.44%-30.91%
Moderna, Inc. stock logo
MRNA
Moderna
-2.65%+0.97%-5.13%-16.21%-83.00%
Qiagen stock logo
QGEN
Qiagen
+1.19%+5.01%+4.40%+15.60%+6.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.4017 of 5 stars
4.52.00.00.03.71.70.6
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
1.9994 of 5 stars
3.02.00.00.02.20.01.9
Moderna, Inc. stock logo
MRNA
Moderna
4.4859 of 5 stars
4.01.00.04.63.12.51.3
Qiagen stock logo
QGEN
Qiagen
3.2298 of 5 stars
1.22.01.74.52.81.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$216.0734.32% Upside
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
2.00
Hold$19.0039.81% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$53.5899.81% Upside
Qiagen stock logo
QGEN
Qiagen
2.30
Hold$48.427.86% Upside

Current Analyst Ratings Breakdown

Latest HCM, MRNA, ASND, and QGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/13/2025
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/12/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
5/5/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$260.00 ➝ $280.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$32.00 ➝ $28.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$368.70M26.60N/AN/A($1.88) per share-85.56
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$630.20M3.76$0.55 per share24.51$4.27 per share3.18
Moderna, Inc. stock logo
MRNA
Moderna
$3.14B3.30N/AN/A$28.33 per share0.95
Qiagen stock logo
QGEN
Qiagen
$2.00B4.98$3.74 per share12.01$16.08 per share2.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$6.28N/A670.23N/A-104.54%N/A-39.23%N/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$100.78MN/A0.009.31N/AN/AN/AN/A6/18/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-110.04%-28.74%-21.83%8/7/2025 (Estimated)
Qiagen stock logo
QGEN
Qiagen
$83.59M$0.40125.0018.252.394.23%13.92%8.40%7/30/2025 (Estimated)

Latest HCM, MRNA, ASND, and QGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Qiagen stock logo
QGEN
Qiagen
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Qiagen stock logo
QGEN
Qiagen
$0.250.56%N/A62.50%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.17
0.84
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
0.07
2.81
2.68
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Qiagen stock logo
QGEN
Qiagen
0.38
3.61
3.09

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
8.82%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Qiagen stock logo
QGEN
Qiagen
70.00%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
3.60%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Qiagen stock logo
QGEN
Qiagen
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
64060.97 million36.41 millionOptionable
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
1,760174.32 million168.04 millionNot Optionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.74 million324.40 millionOptionable
Qiagen stock logo
QGEN
Qiagen
6,030222.29 million201.89 millionOptionable

Recent News About These Companies

Qiagen stock logo
Qiagen (NYSE:QGEN) Releases FY 2025 Earnings Guidance
Contrasting Genfit (NASDAQ:GNFT) and Qiagen (NYSE:QGEN)
Qiagen stock logo
GTS Securities LLC Cuts Stake in Qiagen (NYSE:QGEN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$160.85 +1.62 (+1.01%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$13.59 +0.36 (+2.72%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.82 +0.77 (+2.94%)
As of 11:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Qiagen stock logo

Qiagen NYSE:QGEN

$44.89 +0.51 (+1.15%)
As of 11:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.